Literature DB >> 3085966

Aflatoxin B1 binding to plasma albumin and liver DNA upon chronic administration to rats.

C P Wild, R C Garner, R Montesano, F Tursi.   

Abstract

The hepatocarcinogen aflatoxin B1 (AFB1) was administered to male Wistar rats by oral intubation in either single or repeated doses and the binding to plasma protein and liver DNA determined. Twenty-four hours after a single dose (3.5-200 micrograms/kg AFB1) a constant ratio was found between levels of aflatoxin bound to plasma protein and that bound to liver DNA. In total 0.98-2.15% of the administered dose was bound to the plasma protein at this time point. In the chronic study rats received two doses of 0.5 microgram AFB1/day and groups of animals were killed on days 2, 3, 7, 14, 21 and 24. Binding of aflatoxin to plasma protein accumulated to a level 3-fold higher than that seen after a single dose. Levels of binding reached a plateau between days 7 and 14 of treatment and then remained stable until the end of the experiment. Binding to DNA also accumulated, 2.5-fold and in parallel to plasma protein, binding reached a plateau between days 7 and 14 of treatment. In both the chronic and acute studies fractionation of the plasma proteins by Sephadex G-200 chromatography showed that all detectable bound aflatoxin was associated with a single peak corresponding to albumin. Thus, a constant ratio was observed, after chronic or single exposure, between the concentration of plasma albumin-bound aflatoxin and that bound to DNA of the liver, the target organ for carcinogenesis by AFB1. In order to investigate the proposed role of AFB1 in the aetiology of primary hepatocellular carcinoma in man it would be of great value to have a method for assessing long-term human exposure at an individual level. The relevance of the observations presented in this paper are discussed in the light of such a requirement.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3085966     DOI: 10.1093/carcin/7.6.853

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  24 in total

1.  Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma.

Authors:  C J Chen; M W Yu; Y F Liaw; L W Wang; S Chiamprasert; F Matin; A Hirvonen; D A Bell; R M Santella
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

2.  Intercellular variation in levels of adducts of aflatoxin B1 and G1 in DNA from rat tissues: a quantitative immunocytochemical study.

Authors:  C P Wild; R Montesano; J Van Benthem; E Scherer; L Den Engelse
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 3.  Estimation of exposure of man to substances reacting covalently with macromolecules.

Authors:  P B Farmer; H G Neumann; D Henschler
Journal:  Arch Toxicol       Date:  1987-06       Impact factor: 5.153

4.  Physiologically based toxicokinetics of serum aflatoxin B1-lysine adduct in F344 rats.

Authors:  Guoqing Qian; Lili Tang; Franklin Wang; Xia Guo; Michael E Massey; Jonathan H Williams; Timothy D Phillips; Jia-Sheng Wang
Journal:  Toxicology       Date:  2012-11-09       Impact factor: 4.221

5.  Aflatoxin-lysine adducts in blood serum of the Malawian rural population and aflatoxin contamination in foods (groundnuts, maize) in the corresponding areas.

Authors:  Anitha Seetha; Emmanuel S Monyo; Takuji W Tsusaka; Harry W Msere; Frank Madinda; Tiyamika Chilunjika; Ethel Sichone; Dickson Mbughi; Benson Chilima; Limbikani Matumba
Journal:  Mycotoxin Res       Date:  2018-04-20       Impact factor: 3.833

6.  Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan.

Authors:  Hui-Chen Wu; Qiao Wang; Hwai-I Yang; Habibul Ahsan; Wei-Yann Tsai; Li-Yu Wang; Shu-Yuan Chen; Chien-Jen Chen; Regina M Santella
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03       Impact factor: 4.254

7.  Distribution and induction of aflatoxin B1-9a-hydroxylase activity in rat liver parenchymal and non-parenchymal cells.

Authors:  M Gemechu-Hatewu; K L Platt; F Oesch; P Steinberg
Journal:  Arch Toxicol       Date:  1996       Impact factor: 5.153

8.  Alteration of biogenic amines in mouse brain regions by alkylating agents. I. Effects of aflatoxin B1 on brain monoamines concentrations and activities of metabolizing enzymes.

Authors:  S Jayasekara; D B Drown; R A Coulombe; R P Sharma
Journal:  Arch Environ Contam Toxicol       Date:  1989 May-Jun       Impact factor: 2.804

9.  Long-term stability of human aflatoxin B1 albumin adducts assessed by isotope dilution mass spectrometry and high-performance liquid chromatography-fluorescence.

Authors:  Peter F Scholl; John D Groopman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06       Impact factor: 4.254

10.  Complete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold.

Authors:  Natalie M Johnson; Patricia A Egner; Victoria K Baxter; Michael B Sporn; Ryan S Wible; Thomas R Sutter; John D Groopman; Thomas W Kensler; Bill D Roebuck
Journal:  Cancer Prev Res (Phila)       Date:  2014-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.